Gain Therapeutics Q4 2024 Earnings Report

Gain Therapeutics EPS Results

• Actual EPS: -$0.11
• Consensus EPS: -$0.18
• Beat/Miss: Beat by +$0.07
• One Year Ago EPS: N/A

Gain Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Gain Therapeutics Announcement Details

• Quarter: Q4 2024
• Date: 3/27/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, March 27, 2025
• Conference Call Time: 1:30PM ET

Gain Therapeutics (NASDAQ:GANX) (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity. In addition to its clinical program, the company is advancing preclinical pipelines targeting Parkinson’s disease and other central nervous system disorders. Using structure-based design and high-throughput screening, Gain seeks to expand its pipeline across multiple indications with high unmet medical need.

Headquartered in Geneva, Switzerland, with research operations in Massachusetts, Gain Therapeutics was founded in 2015 and has since established collaborations with academic centers and industry partners to support its discovery and development efforts. The company is led by a management team with experience in biotechnology, pharmaceutical development, and protein science, guiding Gain through translational research toward clinical validation.